Hong Kong IPO disclosure precedents · 138 companies, 139 items
General related-party/connected transactions entered into in the track record, disclosed per the accountant's report, which are trade in nature and conducted on arm's-length or normal commercial terms.
The Group has, in its ordinary and usual course of business, entered into the following transactions with CXMT Group which are expected to continue after the Listing.
Business · p. 226
As of the Latest Practicable Date, the Company had complied with such internal control measures, including, where applicable, the Shareholders’ approval for the transactions under the DRAM Provision Agreements.
During the Track Record Period, our transactions with related parties mainly comprised (i) purchases of property, plant and equipment from an associate, Jiangxi Tungsten Jinxun Resources Africa SAS; (ii) leasing of offices, staff dormitories and warehouse; and (iii) interest income earned from an associate from provision of a loan.
Financial Information · p. 338
It is the view of our Directors that each of the related party transactions set out in Note 33 of the Accountants' Report in Appendix I to this prospectus (i) were conducted on normal commercial terms and/or on terms not less favorable than terms available from Independent Third Parties, which are considered fair, reasonable and in the interest of our Shareholders as a whole; and (ii) do not distort our Track Record Period results or make our historical results not reflective of future performance.
Financial Information · p. 338
Our Directors confirm that all the guaranteed bank and other borrowings were released.
We entered into transactions with our related parties in the ordinary course of our business from time to time, including: (i) purchase and sale of goods; (ii) provision of services; (iii) leasing and
Financial Information · p. 348
These related party transactions were conducted on an arm’s length basis and on normal commercial terms between the relevant parties. We are expected to continue entering into contracts for related party transactions of the foregoing nature as part of our ordinary business from time to time.
Financial Information · p. 348
Our Directors believe that our transactions with related parties during the Track Record Period and up to the Latest Practicable Date were conducted in the ordinary course of business and on an arm’s length basis, and they did not distort our results of operations or make our historical results not reflective of our future performance.
During the Track Record Period, we sold GPGPU products to Customer L, amounting to RMB85.1 million in aggregate, representing 6.3% of our total sales for the same period.
Business · p. 209
Our unlisted equity investment increased from RMB50.0 million as of December 31, 2022 to RMB90.7 million as of December 31, 2023, primarily due to our investment in a subsidiary of Customer L (one of our five largest customers in 2022 and 2023), which engaged in a data infrastructure development project, for potential business opportunities.
Financial Information · p. 310
Our Directors are of the view that each of the related party transactions was conducted in the ordinary and usual course of business and on normal commercial terms between the relevant parties and does not distort our Track Record Period results or make our historical results not reflective of future performance.
Our Directors are of the view that each of our transactions with related parties during the Track Record Period were conducted in the ordinary course of business on an arm’s length basis and with normal commercial terms between the relevant parties.
Financial Information · p. 288
Our Directors are also of the view that our related party transactions during the Track Record Period would not distort our results of operations or cause our historical results to become non-reflective of our future performance.
To the best of our knowledge, except for Jiangsu Sunview Garments Co., Ltd., which is a connected person, all store partners were Independent Third Parties as of the Latest Practicable Date.
Business · p. 208
All key terms of the agreements with Jiangsu Sunview Garments Co., Ltd. and these 34 store partners are generally comparable with those with other parties after negotiated on an arm's length basis.
Business · p. 208
Our Directors believe that our transactions with related parties during the Track Record Period were conducted on an arm's length basis, and they did not distort our results of operations or make our historical results not reflective of our future performance.
The below table sets forth material transactions between us and our related parties during the Track Record Period.
Financial Information · p. 420
Purchases of CRO services from: WuXi Group
Financial Information · p. 420
To the best of our knowledge, except for WuXi AppTec, none of them has any past or present relationships with us, our Directors, shareholders, senior management or any of their respective associates.
During the Track Record Period, other than the compensation to our key management personnel, we had certain related party transactions with our key management personnel, details of which are set out in note 35 to the Accountants' Report in Appendix I to this document.
As of December 31, 2023 and 2024 and August 31, 2025, our related party transactions were compensation for the services purchased from our related parties, mainly including conducting preclinical trials for our pipeline products and manufacturing of active pharmaceutical ingredients for HX301 and small molecule raw materials.
Financial Information · p. 494
It is the view of our Directors that our related party transactions during the Track Record Period (i) were conducted in the ordinary and usual course of business and on normal commercial terms between the relevant parties; and (ii) do not distort our Track Record Period results or make our historical results not reflective of future performance.
During the Track Record Period, we entered into transactions with certain of our related parties, such as engaging in futures trading, subscribing to funds and asset management products, subscribing to subordinated debts and engaging in OTC derivatives transactions.
Financial Information · p. 395
Our Directors believe that these related party transactions were carried out on an arm's-length basis and would not distort our results of operations during the Track Record Period or cause such results not to be reflective of our future performance.
Our current amounts due to related parties decreased from HK$347.2 million as of December 31, 2022 to HK$240.4 million as of December 31, 2023, and increased to HK$432.1 million as of December 31, 2024, primarily attributed to the variation of amounts due to parties under common control of ultimate controlling party representing IT services payable rendered by related parties.
Financial Information · p. 456
Except for amount due to related parties as disclosed in Note 36 to the Accountants' Report set out in Appendix I, all amount due to related parties are in non-trade nature, and such amounts will be settled prior to the Listing.
Financial Information · p. 456
As of October 31, 2025, all of our amounts due to related parties were trade in nature.
These transactions primarily included but not limited to (i) sales and purchases of products, materials and equipment; (ii) provision of services to related parties, including epitaxial wafers-related services; (iii) leases in relation to property, plant and equipment; and (iv) loans and borrowings from/to related parties.
Financial Information · p. 426
All loans, advances, non-trade balances due to and from the related parties are expected to be settled before the Global Offering.
Financial Information · p. 426
It is the view of our Directors that our transactions with related parties during the Track Record Period was conducted on an arm’s length basis and with normal commercial terms.
During the Track Record Period, our related party transactions mainly represented our purchase of API with ancillary services and in-licenses from related parties and interests on loan from a related party.
Financial Information · p. 498
The amounts due to Topharman Shanghai represent loan from Topharman Shanghai to Nantong Hefeng with a fixed interest rate of 3.85%. Such non-trade balance due to a related party had been settled as of the date of this prospectus.
Financial Information · p. 499
Our Directors confirm that all material related party transactions during the Track Record Period were conducted on an arm's length basis, and would not distort our results of operations over the Track Record Period or make our historical results over the Track Record Period not reflective of our expectations for our future performance.
Our amounts due to related parties increased by 213.7% from RMB24.8 million as of December 31, 2022 to RMB77.8 million as of December 31, 2023, primarily attributable to an increase in the amounts due to Guangzhou Yuji and its affiliate.
Financial Information · p. 454
As of December 31, 2022, 2023 and 2024, all the balances with related parties were trade in nature, unsecured, interest-free and repayable on demand.
Financial Information · p. 454
Our Directors are of the view that each of the significant related party transactions set out in Note 33 to the Accountants' Report included in Appendix I to this prospectus was conducted on an arm's length basis and would not distort our track record results or make our historical results not reflective of our future performance.
We enter into transactions with our related parties from time to time. For details of our related party transactions, see Note 50 to the Accountants’ Report included in Appendix I to this Prospectus.
Financial Information · p. 359
Our Directors are of the view that each of the related party transactions set out in Note 50 to the Accountants’ Report included in Appendix I to this Prospectus was conducted in the ordinary course of business on an arm’s length basis and with normal commercial terms between the relevant parties.
We entered into supply framework agreements with Guangxi Jiuyun, Mr. Wu Qingtuan and Jiangxi Youyuan (the “Connected Franchisees”), which are our connected persons, pursuant to which our Company will supply tea leaves and other products to them and/or their controlled companies acting as our franchisees.
Business · p. 258
During the Track Record Period, we entered into a number of transactions with related parties, including certain of our Controlling Shareholders, their close family members and companies controlled by them.
Financial Information · p. 459
Our Directors believe that our transactions with related parties during the Track Record Period were conducted in the ordinary course of business and on an arm’s length basis, and they did not distort our track record results or make our historical results not reflective of our future performance.
Our Company has entered into certain continuing connected transactions with our Controlling Shareholders and/or their respective associates.
Summary · p. 23
Our Directors believe that our transactions with related parties during the Track Record Period were conducted on an arm’s-length basis and did not distort our results of operations or make our historical results not reflective of our future performance.
During the Track Record Period, we entered into several CRO agreements with Laibiyi Technology (Xiamen) Co., Ltd.* (萊必宜科技（廈門）有限責任公司) (“Laibiyi Technology”).
Financial Information · p. 426
Under the CRO agreements, Laibiyi Technology is responsible for providing clinical research services for C019199, and BE studies services, such as biological sample analysis and testing services for some of our other drug candidates.
Financial Information · p. 426
Our Directors are of the view that the transactions with Laibiyi Technology were conducted at arm’s length and on normal commercial terms, which are similar to those of other independent service providers.
During the Track Record Period, we purchased various products and services from Beijing Sihuan, including domestic utilities like water, electricity, and heating, as well as packing services for clinical trials and processing services for XZP-3621 preparation.
Financial Information · p. 478
During the Track Record Period, we rented a building from Beijing Sihuan and Hainan Sihuan for office use.
Financial Information · p. 478
We had an outstanding balance due from an entity under common control of the ultimate holding company of RMB23 thousand, RMB0.2 million and RMB0.9 million as of December 31, 2023 and 2024 and June 30, 2025, respectively.
During the Track Record Period, other than (i) compensation of key management personnel of our Group; (ii) the personal guarantee by our Directors for our banking facilities; and (iii) staff costs incurred in respect of the spouse of Mr. KY Ip in the amount of approximately HK$0.3 million and HK$0.2 million for FY2023/24 and FY2024/25, respectively, we do not have other related party transactions.
Financial Information · p. 314
All of our outstanding related party balances will be fully settled before the Listing.